Publications

• Time-to-event prediction in ALS using a landmark modeling approach, using the ALS Natural History Consortium dataset.
  Amyotroph Lateral Scler Frontotemporal Degener Page(s): 1 - 9
  04/02/2025 Authors: Schneck D; Arguedas A; Xenopoulos-Oddsson A; Arcila-Londono X; Lunetta C; Wymer J; Olney N; Gwathmey K; Ajroud-Driss S; Hayat G
• ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression.
  Ann Clin Transl Neurol Volume: 12 Page(s): 714 - 723
  04/01/2025 Authors: Thomas EV; Han C; Kim WJ; Asress S; Li Y; Taylor JA; Gearing M; Fournier CN; McEachin ZT; Seyfried NT
• ALS Motor Observational Telemedicine Objective Rasch-Built Assessment: A Quantitative Scale for the Era of Teleneurology.
  Neurol Clin Pract Volume: 15 Page(s): e200432
  04/01/2025 Authors: Fournier CN; Levine M; Simmons K; Garca-Santibez RC; Rowland A; Quinn CC; Ho DT; Bedlack RS; Glass JD
• The Amyotrophic Lateral Sclerosis Multidisciplinary Clinic: Broke but Not Broken.
  Neurology Volume: 104 Page(s): e210189
  02/25/2025 Authors: Fournier CN; Quinn CC
• Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
  JAMA Netw Open Volume: 8 Page(s): e2459058
  02/03/2025 Authors: Paganoni S; Fournier CN; Macklin EA; Chibnik LB; Quintana M; Saville BR; Detry MA; Vestrucci M; Marion J; McGlothlin A
• Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale as a Novel Tool to Measure Disease Progression.
  Biomedicines Volume: 13
  01/13/2025 Authors: Sun C; Chen Y; Xu L; Wang W; Zhang N; Fournier CN; Li N; Fan D
• Rehabilitation is [still] necessary to optimize function in neuromuscular disorders.
  Muscle Nerve Volume: 71 Page(s): 29 - 32
  01/01/2025 Authors: Omura J; Stratton A; Fournier C; Howard I
• Learning From the Exception and Not the Rule: Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.
  Neurology Volume: 103 Page(s): e209780
  08/27/2024 Authors: Fournier CN
• The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 25 Page(s): 382 - 387
  05/01/2024 Authors: Genge A; Cedarbaum JM; Shefner J; Chio A; Al-Chalabi A; Van Damme P; McDermott C; Glass J; Berry J; van Eijk RPA
• The importance of understanding minimal important difference for ALSFRS-R: A reply to 'Do we really need to calculate a minimal important difference for ALSFRS-R?' https://doi.org/10.1080/21678421.2023.2248199.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 25 Page(s): 216 - 217
  02/01/2024 Authors: Fournier CN; Glass JD
• Healthcare resource utilization at different stages of amyotrophic lateral sclerosis: Results from a real-world survey.
  J Neurol Sci Volume: 452 Page(s): 120764
  09/15/2023 Authors: Stenson K; O'Callaghan L; Mellor J; Wright J; Gibson G; Earl L; Barlow S; Fournier CN
• Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis.
  Ann Neurol Volume: 94 Page(s): 547 - 560
  09/01/2023 Authors: Quintana M; Saville BR; Vestrucci M; Detry MA; Chibnik L; Shefner J; Berry JD; Chase M; Andrews J; Sherman AV
• AIMing for Better Tools to Track Disease Progression.
  Neurology Volume: 101 Page(s): 243 - 244
  08/08/2023 Authors: Fournier CN
• Primary lateral sclerosis natural history study - planning, designing, and early enrollment.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 24 Page(s): 394 - 404
  08/01/2023 Authors: Mitsumoto H; Jang G; Lee I; Simmons Z; Sherman AV; Heitzman D; Sorenson E; Cheung K; Andrews J; Harms M
• Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 24 Page(s): 311 - 316
  05/01/2023 Authors: Fournier CN; James V; Glass JD
• Longitudinal comparison of the self-entry amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-RSE) and rasch-built overall amyotrophic lateral sclerosis disability scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis
  Volume: 66 Page(s): S41 - S41
  11/01/2022 Authors: Johnson S; Burke K; Scheier Z; Keegan M; Clark A; Chan J; Fournier C; Berry J
• Longitudinal comparison of the self-entry Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-RSE) and Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis.
  Muscle Nerve Volume: 66 Page(s): 495 - 502
  10/01/2022 Authors: Johnson SA; Burke KM; Scheier ZA; Keegan MA; Clark AP; Chan J; Fournier CN; Berry JD
• Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data.
  Nat Comput Sci Volume: 2 Page(s): 605 - 616
  05/31/2003 Authors: Ramamoorthy D; Severson K; Ghosh S; Sachs K; Answer ALS; Glass JD; Fournier CN; Pooled Resource Open-Access ALS Clinical Trials Consortium; ALS/MND Natural History Consortium; Herrington TM
• Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 23 Page(s): 424 - 429
  08/01/2022 Authors: Manera U; Solero L; Fournier CN; Canosa A; Vasta R; Bombaci A; Grassano M; Palumbo F; Torrieri MC; Salamone P
• Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.
  Neurotherapeutics Volume: 19 Page(s): 1180 - 1192
  07/01/2022 Authors: Fournier CN
• Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial.
  J Neurol Neurosurg Psychiatry Volume: 93 Page(s): 871 - 875
  05/16/2022 Authors: Paganoni S; Hendrix S; Dickson SP; Knowlton N; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB; Owegi MA
• Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.
  Ann Neurol Volume: 91 Page(s): 165 - 175
  02/01/2022 Authors: Paganoni S; Berry JD; Quintana M; Macklin E; Saville BR; Detry MA; Chase M; Sherman AV; Yu H; Drake K
• Unintended Consequences of Approving Unproven Treatments-Hope, Hype, or Harm?
  JAMA Neurol Volume: 79 Page(s): 117 - 118
  02/01/2022 Authors: Glass JD; Fournier CN
• Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 23 Page(s): 91 - 99
  02/01/2022 Authors: Hertzberg VS; Singh H; Fournier CN; Moustafa A; Polak M; Kuelbs CA; Torralba MG; Tansey MG; Nelson KE; Glass JD
• Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID-19.
  Muscle Nerve Volume: 64 Page(s): E18 - E20
  10/01/2021 Authors: Galea MD; Galea VP; Eberhart AC; Patwa HS; Howard I; Fournier CN; Bedlack RS
• Chinese validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale.
  Eur J Neurol Volume: 28 Page(s): 1876 - 1883
  06/01/2021 Authors: Sun C; Fournier CN; Ye S; Zhang N; Ma Y; Fan D
• Comparison of Phenotypic Characteristics and Prognosis Between Black and White Patients in a Tertiary ALS Clinic.
  Neurology Volume: 96 Page(s): e840 - e844
  02/09/2021 Authors: Brand D; Polak M; Glass JD; Fournier CN
• Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 22 Page(s): 22 - 32
  01/01/2021 Authors: Beaulieu D; Berry JD; Paganoni S; Glass JD; Fournier C; Cuerdo J; Schactman M; Ennist DL
• Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.
  Muscle Nerve Volume: 63 Page(s): 31 - 39
  01/01/2021 Authors: Paganoni S; Hendrix S; Dickson SP; Knowlton N; Macklin EA; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB
• Preface: promoting research in PLS: current knowledge and future challenges.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 21 Page(s): 1 - 2
  11/01/2020 Authors: Mitsumoto H; Turner MR; all Delegates of the PLS Conference; Ajroud-Driss S; Andres P; Andrews J; Gomez EA; Atehortua JMS; Babu S; Barohn R
• The NEALS primary lateral sclerosis registry.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 21 Page(s): 74 - 81
  11/01/2020 Authors: Paganoni S; De Marchi F; Chan J; Thrower SK; Staff NP; Datta N; Kisanuki YY; Drory V; Fournier C; Pioro EP
• Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
  N Engl J Med Volume: 383 Page(s): 919 - 930
  09/03/2020 Authors: Paganoni S; Macklin EA; Hendrix S; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB; Owegi MA; Quick A
• Tau deposition in the spinal cord is not specific for CTE-ALS.
  Neurology Volume: 95 Page(s): 37 - 39
  07/07/2020 Authors: Fournier CN; Gearing M; Glass JD
• The Rasch-Built Overall ALS Disability Scale: ROADS to a better ALS outcome measure
  Volume: 94
  04/14/2020 Authors: Fournier C; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski K; Tyor W; Hertzberg V; James V; Polak M
• Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
  JAMA Neurol Volume: 77 Page(s): 480 - 488
  04/01/2020 Authors: Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M
• Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scale.
  Muscle Nerve Volume: 61 Page(s): 163 - 172
  02/01/2020 Authors: Mitsumoto H; Chiuzan C; Gilmore M; Zhang Y; Simmons Z; Paganoni S; Kisanuki YY; Zinman L; Jawdat O; Sorenson E
• The gut microbiome and neuroinflammation in amyotrophic lateral sclerosis? Emerging clinical evidence.
  Neurobiol Dis Volume: 135 Page(s): 104300
  02/01/2020 Authors: Fournier CN; Houser M; Tansey MG; Glass JD; Hertzberg VS
• Rare variants in MYH15 modify amyotrophic lateral sclerosis risk.
  Hum Mol Genet Volume: 28 Page(s): 2309 - 2318
  07/15/2019 Authors: Kim H; Lim J; Bao H; Jiao B; Canon SM; Epstein MP; Xu K; Jiang J; Parameswaran J; Li Y
• TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
  Brain Commun Volume: 1 Page(s): fcz014
  01/01/2019 Authors: Lee SM; Asress S; Hales CM; Gearing M; Vizcarra JC; Fournier CN; Gutman DA; Chin L-S; Li L; Glass JD
• Potential Role of the Gut Microbiome in ALS: A Systematic Review.
  Biol Res Nurs Volume: 20 Page(s): 513 - 521
  10/01/2018 Authors: Wright ML; Fournier C; Houser MC; Tansey M; Glass J; Hertzberg VS
• Reader response: Pathologic Thr175 tau phosphorylation in CTE and CTE with ALS.
  Neurology Volume: 91 Page(s): 578 - 579
  09/18/2018 Authors: Glass JD; Fournier CN; Gearing M
• Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: Real world experience from 27 centres.
  Clin Neurophysiol Volume: 129 Page(s): 1756 - 1762
  08/01/2018 Authors: Neuwirth C; Braun N; Claeys KG; Bucelli R; Fournier C; Bromberg M; Petri S; Goedee S; Lenglet T; Leppanen R
• An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 19 Page(s): 242 - 249
  05/01/2018 Authors: Fournier CN; Schoenfeld D; Berry JD; Cudkowicz ME; Chan J; Quinn C; Brown RH; Salameh JS; Tansey MG; Beers DR
• Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis.
  Ann Neurol Volume: 82 Page(s): 139 - 146
  07/01/2017 Authors: Gendron TF; C9ORF72 Neurofilament Study Group; Daughrity LM; Heckman MG; Diehl NN; Wuu J; Miller TM; Pastor P; Trojanowski JQ; Grossman M
• ALSUntangled No. 37: Inosine.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 18 Page(s): 309 - 312
  05/01/2017 Authors: ALSUntangled Group
• Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis.
  Sci Transl Med Volume: 9
  03/29/2017 Authors: Gendron TF; Chew J; Stankowski JN; Hayes LR; Zhang Y-J; Prudencio M; Carlomagno Y; Daughrity LM; Jansen-West K; Perkerson EA
• ALSUntangled No. 36: Accilion.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 18 Page(s): 142 - 147
  02/01/2017 Authors: ALSUNTANGLED GROUP
• ALSUntangled 38: L-serine.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 18 Page(s): 148 - 151
  02/01/2017 Authors: ALSUntangled Group
• Predicting disease progression in amyotrophic lateral sclerosis.
  Ann Clin Transl Neurol Volume: 3 Page(s): 866 - 875
  11/01/2016 Authors: Taylor AA; Fournier C; Polak M; Wang L; Zach N; Keymer M; Glass JD; Ennist DL; Pooled Resource OpenAccess ALS Clinical Trials Consortium
• Is C9orf72 ALS Different from Sporadic Disease? A Comparative Study in an ALS Clinic Population
  Volume: 80 Page(s): S170 - S170
  10/01/2016 Authors: Umoh M; Fournier C; Li Y; Polak M; Shaw L; Hu W; Gearing M; Glass J
• Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population.
  Neurology Volume: 87 Page(s): 1024 - 1030
  09/06/2016 Authors: Umoh ME; Fournier C; Li Y; Polak M; Shaw L; Landers JE; Hu W; Gearing M; Glass JD
• Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials.
  Neurology Volume: 87 Page(s): 392 - 400
  07/26/2016 Authors: Glass JD; Hertzberg VS; Boulis NM; Riley J; Federici T; Polak M; Bordeau J; Fournier C; Johe K; Hazel T
• ALS Untangled No.33 Endotherapia
  AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION Volume: 17 Page(s): 461 - 465
  07/01/2016 Authors: Bedlack R; Quinn C; Karam C; Sherman A; Ostrow L; Hardiman O; Heiman-Patterson T; Gutmann L; Bromberg M; Carter G
• ALSUntangled No. 32: Gluten-free diet
  AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION Volume: 17 Page(s): 307 - 309
  03/01/2016 Authors: Bedlack R; Quinn C; Karam C; Sherman A; Ostrow L; Hardiman O; Heiman-Patterson T; Gutmann L; Bromberg M; Carter G
• Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population.
  J Clin Neuromuscul Dis Volume: 17 Page(s): 99 - 105
  03/01/2016 Authors: Fournier CN; Murphy A; Loci L; Mitsumoto H; Lomen-Hoerth C; Kisanuki Y; Simmons Z; Maragakis NJ; McVey AL; Al-Lahham T
• ALSUntangled No. 34: GM604.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 17 Page(s): 617 - 621
  01/01/2016
• ALSUntangled No. 35: Hyperbaric Oxygen Therapy.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 17 Page(s): 622 - 624
  01/01/2016 Authors: ALSUntangled Group
• ALSUntangled No. 27: Precision Stem Cell
  AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION Volume: 16 Page(s): 282 - 285
  06/01/2015 Authors: Valor E; Bedlack R; Quinn C; Karam CC; Sherman A; Ostrow L; Hardiman O; Heiman-Patterson T; Gutmann L; Bromberg M
• Head injury does not alter disease progression or neuropathologic outcomes in ALS.
  Neurology Volume: 84 Page(s): 1788 - 1795
  04/28/2015 Authors: Fournier CN; Gearing M; Upadhyayula SR; Klein M; Glass JD
• ALSUntangled: introducing The Table of Evidence.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 16 Page(s): 142 - 145
  03/01/2015 Authors: ALSUntangled Group
• ALSUntangled No. 29: MitoQ.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 16 Page(s): 427 - 429
  01/01/2015 Authors: ALSUntangled Group
• Modeling the course of amyotrophic lateral sclerosis.
  Nat Biotechnol Volume: 33 Page(s): 45 - 47
  01/01/2015 Authors: Fournier C; Glass JD
• ALSUntangled No. 26: lunasin.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 15 Page(s): 622 - 626
  12/01/2014 Authors: ALSUntangled Group
• ALSUntangled No. 22: Propofol
  AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION Volume: 14 Page(s): 640 - 642
  12/01/2013 Authors: Ostrow L; Bedlack R; Hardiman O; Heiman-Patterson T; Gutmann L; Bromberg M; Carter G; Kabashi E; Bertorini T; Mozaffar T
• Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 14 Page(s): 632 - 634
  12/01/2013 Authors: Quinn C; Macklin EA; Atassi N; Bowser R; Boylan K; Cudkowicz M; Fournier C; Ladha SS; Lacomis D; Berry J
• ALS Untangled No. 21: Fecal transplants
  AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION Volume: 14 Page(s): 482 - 485
  09/01/2013 Authors: Ostrow L; Bedlack R; Hardiman O; Heiman-Patterson T; Gutmann L; Bromberg M; Carter G; Kabashi E; Bertorini T; Mozaffar T
• ALS Untangled No. 20: the Deanna protocol.
  Amyotroph Lateral Scler Frontotemporal Degener Volume: 14 Page(s): 319 - 323
  05/01/2013 Authors: ALSUntangled Group; Fournier C; Bedlack B; Hardiman O; Heiman-Patterson T; Gutmann L; Bromberg M; Ostrow L; Carter G; Kabashi E
• ANNA-1 (anti-Hu) associated sensory neuronopathy with malignant mixed mullerian tumor.
  Muscle Nerve Volume: 47 Page(s): 776 - 777
  05/01/2013 Authors: Fournier CN; Kalra A; Lachance DH; Zarwan C; Srinivasan J
• ALSUntangled No. 19: Sodium chlorite
  AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION Volume: 14 Page(s): 236 - 238
  04/01/2013 Authors: Bedlack R; Hardiman O; Heiman-Patterson T; Gutmann L; Bromberg M; Ostrow L; Carter G; Kabashi E; Bertorini T; Mozaffar T
• Pachymeningeal enhancement in baroreflex failure syndrome.
  Neurology Volume: 75 Page(s): 375
  07/27/2010 Authors: Fournier C; Srinivasan J
• Gene therapy, cell transplantation and stroke.
  Front Biosci Volume: 11 Page(s): 1090 - 1101
  01/01/2006 Authors: Borlongan CV; Fournier C; Stahl CE; Yu G; Xu L; Matsukawa N; Newman M; Yasuhara T; Hara K; Hess DC
• Transplantation of carotid body cells in the treatment of neurological disorders.
  Neurosci Biobehav Rev Volume: 28 Page(s): 803 - 810
  01/01/2005 Authors: Yu G; Fournier C; Hess DC; Borlongan CV